Support Haematologica and Open Access Publishing by becoming a member of the European Hematology Association (EHA) and enjoying the benefits of this membership, which include free participation in the online CME program 
1

INTRODUCTION
Hepcidin is a liver-secreted peptide hormone that has emerged as the central regulator of body iron homeostasis. Circulating hepcidin binds to the iron export protein ferroportin, which is located on the surface of enterocytes, macrophages and other cells, and causes its internalisation and degradation (1) . This in turn leads to reduced iron mobilization from these cells and, in the case of the small intestine, decreased iron absorption (2) .
Hepatic hepcidin expression is influenced by changes in body iron stores, the rate of erythropoiesis, systemic inflammation, and other stimuli (2) (3) (4) . Under normal conditions, hepcidin levels are inversely related to body iron stores, increasing in response to iron loading and decreasing with iron deficiency (2) .
This feedback mechanism allows hepcidin to regulate body iron levels, increasing absorption when body iron demand is high and limiting absorption when the body is iron replete. An increase in the rate of erythropoiesis leads to a decrease in hepcidin levels, thereby increasing iron release from storage sites and iron absorption to supply the iron required for new red blood cell synthesis (4) (5) (6) . The regulation of hepcidin in response to changes in the rate of erythropoiesis is likely to be multifactorial, reflecting iron supply, hypoxia and possibly erythroid-specific factors. Candidates for the latter include growth differentiation factor 15 (GDF15) (7) and twisted gastrulation (TWSG1) (8) . Inflammation and infection stimulate hepcidin production and this leads to iron sequestration in macrophages and a subsequent decrease in plasma iron 5 levels (3, 9) . If inflammation persists, anaemia may result and this condition is called the anemia of chronic disease or the anemia of inflammation (9) .
How these various stimuli alter hepcidin expression is now at least partly understood. The bone morphogenetic proteins (BMPs) appear to play a particularly important role in this process. Several members of this protein family, such as BMPs 2, 4, 6 and 9, have been shown to stimulate hepcidin expression in vitro (10, 11) , but recent studies indicate that the iron-regulated BMP6 is likely to be the most important BMP in regulating hepcidin in vivo (12) . The BMPs act by binding to BMP receptors I and II and the co-receptor hemojuvelin (HJV) on the plasma membrane to initiate a signalling cascade that leads to phosphorylation and activation of SMADs 1/5/8 (13) . These activated SMADs further bind to the co-SMAD, SMAD4, and the complex translocates to the nucleus to enhance hepcidin expression (13) . A soluble form of HJV, inhibitory members of BMP group, such as GDF15, decrease hepcidin levels, likely by inhibiting various aspects of the BMP/SMAD pathway (7, 14) . Other proteins known to be involved in hepcidin regulation are the transmembrane serine protease, matriptase-2 (TMPRSS6), HFE and TfR2. TMPRSS6 inhibits hepcidin expression by cleaving HJV (15) (16) (17) (18) . HFE and TfR2 are able to stimulate hepcidin expression, but how they do so has yet to be resolved. Mutations in HFE, TfR2, HJV and hepcidin lead to body iron loading in humans, whereas TMPRSS6 mutations lead to iron deficiency anaemia (16, 17, (19) (20) (21) .
Inflammatory cytokines such as IL-6 stimulate hepcidin expression by activating the JAK/STAT pathway. Ligation of the IL-6 receptor leads to phosphorylation of STAT3, which then dimerizes and moves to the nucleus where it can activate HAMP transcription (22, 23) . Of particular interest is the finding that the BMP-SMAD and JAK-STAT pathways are interconnected in the regulation of hepcidin. Hamp expression in SMAD4 knockout mice does not respond to IL-6 stimulation and it has been demonstrated that a functional BMP-response element in the HAMP promoter is required for the gene to respond to IL-6 (24, 25) . Taken together, these data suggest that there is cross-talk between the JAK/STAT and BMP/SMAD pathways. They also imply that the regulation of hepcidin by one stimulus may be influenced by other stimuli acting in a different manner. Moreover, in an intact organism, multiple stimuli are likely to be affecting hepcidin expression at any one time. These factors may reinforce each other or they may be antagonistic.
In the present study we have examined the response of the Hamp gene to simultaneous stimuli. We observed that the decrease in hepcidin levels following the stimulation of erythropoiesis with PHZ treatment in Sprague Dawley (SD) rats was overcome by acute inflammation induced by LPS injection. However, the decrease in hepcidin levels due to severe iron deficiency was only partially overcome by LPS treatment. This inhibitory effect of iron deficiency appears to be in part due to a decrease in the generalised response of macrophages to LPS and in part due to a decreased response of hepatocytes to proinflammatory cytokines.
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MATERIAL AND METHODS
Animals, diets, treatments and tissue collection
Sprague Dawley (SD) rats were obtained from the Animal Resources Centre, Western Australia. All animals investigated were of same sex for a given set of experiments and were 9-10 weeks of age. Both male and female rats responded similarly to the same stimuli, although the baseline iron levels of males and females differ (females are higher) as previously described (26, 27) . To induce iron deficiency, animals were maintained on a semi-synthetic iron-deficient diet (3 mg/kg wet weight) for 6 weeks before investigation as previously described (2) . Control rats were maintained on an iron replete diet 
Assessment of hematologic parameters and hepatic iron levels
Hematocrits were measured by the microcapillary method. Serum iron and transferrin saturation were measured using an Iron and Iron Binding Capacity Kit (Sigma-Aldrich). To measure hepatic iron concentration, a small amount of liver from each animal was dried overnight at 110°C, and tissue nonheme iron content determined colorimetrically as previously described (2) .
Cell culture and treatments
HuH7 and RAW 264.7 cells were cultured in RPMI1640 medium supplemented with 10% fetal bovine serum. Primary hepatic macrophages (Kupffer cells) were a gift from Dr Richard Ruddell (QIMR) and were isolated as previously described (29) . In some experiments, cells were pretreated for 6 hours with either 20µM desferrioxamine (DFO), 25µM salicylaldehyde isonicotinoyl hydrazone (SIH; Kindly supplied by Professor Paul Bernhardt, University of Queensland) or medium alone, before overnight incubation with IL-6 (20 ng/mL, Sigma-Aldrich) or LPS (200 ng/mL, Sigma-Aldrich).
RNA extraction and real-time PCR
Total RNA was extracted from tissue samples or cultured cells using TRIzol reagent (Invitrogen, Melbourne, Australia) as per the manufacturer's instructions. Total RNA (1-2 µg) was reverse transcribed with Superscript III (Invitrogen, Melbourne, Australia) to synthesize cDNA. Real-time PCR was performed on this cDNA using SYBR green mix (ABI, Melbourne, Australia) in a RotorGene 3000 (Corbett Life Science, Sydney, Australia) real time PCR 9 machine. The data were analysed by calculating the concentration of a sample from its C t value using a standard curve on the RotorGene software.
The primers used for Hamp were GCTGCCTGTCTCCTGCTTCT and CTGCAGAGCCGTAGTCTGTCTCGTC; and for the inflammatory marker α2-macroglobulin (α2m) were TTGCTGACGTGAAGATGGTG and GCTGAACCGTGA AGGACAAG. The expression data were normalised to the expression of basic transcription factor 3 (BTF3) (primers TGGCAGCAAACACCTTCACC and AGCTTC AGCCAGTCTCCTCAAAC) for rats and to GAPDH for the cell lines (primers GAAGATGGTGATGGGATTTC and GAAGGTGAAGGTCGGAGTC).
Western blot analysis
The cells were washed with 1x PBS and then lysed in 1x SDS sample buffer (62.5 mM Tris-HCl (pH 6.8 at 25°C), 2% w/v SDS, 10% glycerol, 50 mM DTT, 0.01% w/v bromophenol blue) and Western blotting was carried out according to the manufacturer's recommendations. A rabbit polyclonal antibody to phospho-NFκB p65 (1 in 1000 dilution; Cell Signaling Technology) was used to assess NFκB activation. Total NFκB p65 (1 in 1000 dilution; Cell Signaling Technology) was used to assess the proportion of activated p65.
IL-6 and TNFα measurements
ELISA assays for IL-6 and TNFα (R&D Systems, Minneapolis, USA) were performed on serum according to the manufacturer's instructions.
Statistical analysis
The results were analysed using ANOVA with Tukey's post hoc test. p values below 0.05 were considered to be statistically significant. The results are presented as mean ± SEM.
RESULTS
Response of Hamp and α2m to an inflammatory stimulus is not affected by stimulated erythropoiesis
Enhanced erythropoiesis secondary to hemolysis has been shown to repress hepcidin expression (4) whereas inflammation is known to induce it (3). We first examined the net effect of increased erythropoiesis (following PHZinduced hemolysis) and inflammation on hepcidin expression in rats. Data from female rats are shown. Four days after PHZ treatment, animals demonstrated lower hematocrits than vehicle-treated controls (Table 1 ) and a profound reticulocytosis (data not shown). Serum iron levels could not be determined reliably in heavily hemolyzed samples. The hepatic iron concentration in PHZ treated animals was significantly higher than that of control rats (p=<0.001) ( Table 1) , consistent with hepatic scavenging of hemoglobin and heme-derived iron following hemolysis (4). LPS treatment had no significant effect on hematocrit or hepatic iron concentration (Table 1) .
Hepatic Hamp mRNA levels were 7 fold lower in PHZ-treated animals relative to saline-treated control rats, whereas animals injected with LPS alone showed a 4.2-fold increase in Hamp expression (p<0.001) ( Figure 1A ). Alpha 2 macroglobulin (α2m), a marker of inflammation, showed a 60 fold increase following LPS treatment (p<0.001), but was unchanged after PHZ administration ( Figure 1B ). Rats treated with PHZ to induce hematopoiesis, then 4 days later treated with LPS for 6 hours, showed significantly higher Hamp levels (4.2 fold; p<0.001) than controls, and this was not significantly different from the level reached in rats treated with LPS alone (p=0.339) ( Figure 1A) . Similarly, the induction of α2m mRNA expression in animals treated with PHZ and LPS was not significantly different from rats treated with LPS alone ( Figure 1B ). These data suggest that hepcidin response to LPS is not inhibited by induction of erythropoiesis by a relatively high dose of PHZ.
Iron deficiency blunts the Hamp and α2m responses to LPS
Chronic iron deficiency leads to a decrease in hepcidin levels whereas an inflammatory stimulus stimulates hepcidin expression. We thus investigated the effects of an inflammatory stimulus (LPS injection) on Hamp expression in the setting of chronic iron deficiency in rats. Data from male rats are shown.
After being maintained on an iron deficient diet for six weeks, rats had significantly lower hematocrits (P<0.001), serum iron levels (p<0.001) and hepatic iron concentrations (p<0.001) than animals on an iron replete diet (Table 2) . LPS treatment caused a significant decrease in serum iron in animals on the control diet (p<0.01), however, there was no additional effect of LPS in iron deficient rats as these animals already had very low serum iron levels. There was no significant effect of LPS administration on hepatic iron concentration ( Table 2 ). Although the difference was not significant, serum and liver iron levels were slightly higher in LPS-treated iron deficient animals than iron deficient animals alone. It has previously been shown that LPS can predispose erythrocytes to haemolysis (30) and it is possible that such an effect is being observed here as haemolysis would be expected to raise both serum and hepatic iron.
In rats maintained on an iron deficient diet for 6 weeks, Hamp levels were virtually undetectable and were at least 1000 fold lower than those in animals on a control diet (Figure 2A ). Treatment of rats on an iron replete diet with LPS for 6 hours led to a 5.5 fold increase in HAMP relative to saline treated animals (p<0.001). When rats that had been maintained on an iron deficient diet for 6 weeks were treated with LPS, Hamp expression also increased significantly (a precise fold induction is difficult to give as basal hepcidin levels were so low), but the level reached remained significantly lower than that achieved in animals on a control diet (Figure 2A ).These data suggest that an adequate iron level is essential for Hamp to respond fully to LPS. To investigate this further, we demonstrated that the mRNA encoding the inflammatory marker α2m also showed a less robust induction in response to LPS in iron deficient animals than in control animals (p<0.001) ( Figure 2B ).
Iron deficiency alone did not alter α2m mRNA levels ( Figure 2B ). This latter result suggests that the observed effects on Hamp do not simply represent the superimposition of the iron deficiency and LPS treatments and that there is a specific role for iron in the response to LPS.
Iron deficiency inhibits LPS-induced TLR signalling
LPS is a ligand for TLR4 and initiates signalling cascades that lead to an increase in the secretion of pro-inflammatory cytokines such as IL-6 and TNFα by macrophages and other cells. To further examine the effects of iron deficiency on LPS action, we measured serum IL-6 and TNFα levels by ELISA in each of our treatment groups. The levels of both cytokines did not change significantly in animals on an iron deficient diet relative to the controls, however, following LPS treatment, the concentrations of both IL-6 and TNFα achieved were significantly lower in animals on an iron deficient diet than in those on a control diet ( Figure 3A, B) . Consistent with this result, we found that RAW264.7 cells (a macrophage cell line) treated with iron chelators showed a blunted IL-6 mRNA response following LPS treatment relative to cells treated with LPS alone (Figure 4 ).
The production of IL-6 and TNFα in response to LPS has been shown to be mediated by activation of the NFκB pathway (31, 32) . In primary hepatic macrophages stimulated with LPS, we found impaired activation of NFκB (as assessed by determining the level of phosphorylated p65) after prior treatment with the iron chelator DFO ( Figure 5 ). These results are consistent with previously published data in which hepatic macrophages with increased iron content had increased NFκB activation and enhanced expression of proinflammatory genes such as IL-6 (33, 34) , and also with reports that iron chelation reduces the DNA binding activity of NFκB (32) . Taken together, these findings suggest that animals and cells deficient of iron have reduced TLR4 signalling and a blunted inflammatory response to LPS that indirectly contributes to lower hepcidin levels.
Iron deficiency ameliorates IL-6 dependent stimulation of Hamp expression in liver-derived Huh7 cells
The data presented above demonstrate that one mechanism by which iron deficiency ameliorates the Hamp response to LPS is through reduced expression of proinflammatory cytokines such as IL-6. It is also feasible that iron depletion has additional roles and reduces the response of hepatic parenchymal cells to IL-6. We investigated this in HuH7 cells, a human hepatoma cell line. IL-6 has been shown to signal via the JAK/STAT pathway to increase hepcidin levels in hepatocytes. Consistent with published data, Hamp mRNA levels were increased in IL-6 treated Huh7 cells ( Figure 6A ).
However, in the presence of the iron chelator DFO, the Hamp response to IL-6 was reduced ( Figure 6A ). LPS itself did not have a direct stimulatory effect on hepcidin expression in these cells, whereas DFO treatment alone was able to reduce hepcidin expression ( Figure 6A ). To ensure that DFO was depleting iron in these cells, we measured the expression of TfR1 mRNA and found it to be increased as expected ( Figure 6B ). These data suggest that iron deficiency could also directly contribute towards lower hepcidin levels in the hepatocytes.
DISCUSSION
In this study we have investigated the interactions between various systemic stimuli that regulate hepcidin. Different stimuli modulate hepcidin expression in different ways, and the final hepcidin level is determined by the combination of various stimuli acting simultaneously. We have demonstrated that acute inflammation can induce hepcidin expression even in the presence of increased erythropoiesis, indicating that the inflammatory regulator is able to override the erythropoiesis regulator. In contrast, chronic iron deficiency was able to ameliorate the inflammatory response and reduce hepcidin expression. This effect appears to be mediated at least in part through iron depletion interfering with the NFκB signalling pathway.
The major stimuli that alter hepcidin expression are now well delineated.
Increased body iron stores and inflammation can increase hepcidin levels, while iron deficiency, increased erythropoiesis and hypoxia can reduce levels of this iron regulatory hormone (2-4). Understanding how these factors interact to influence the net hepcidin response requires knowledge of the molecular pathways by which they affect HAMP gene transcription. There have been significant advances in this area in recent years, and the BMP/SMAD and JAK/STAT signalling pathways have emerged as being particularly important in controlling hepcidin expression (13, 22, 23) . The former appears to be required for the response of hepcidin to changes in iron stores and erythropoiesis, while the latter is necessary for hepcidin to respond to inflammatory stimuli.
The erythropoietic response of hepcidin is multifactorial, reflecting hypoxia, limitations in iron supply and erythroid-specific factors, but the overall control mechanism likely depends on BMP/SMAD signalling. In contrast, inflammatory stimuli increase cytokine IL-6 expression and this in turn activates the JAK/STAT pathway to induce HAMP transcript levels (22, 23) .
However, in SMAD4 knockout mice, IL-6 has little effect on hepcidin expression, indicating that the BMP/SMAD pathway also is required for an inflammatory response (25) . The interaction between the JAK/STAT and the BMP/SMAD pathways is also evident from the demonstration that soluble HJV, which interacts with BMP receptors to displace membrane-bound HJV and thereby inhibit SMAD activation, inhibits IL-6 stimulated hepcidin expression (14) . Similarly, the BMP inhibitor protein noggin can inhibit IL-6 induced expression of hepcidin in hepatocytes (13) , and Dorsomorphin, a specific SMAD1/5/8 inhibitor, has also been reported to abolish hepcidin response to IL-6 (35) . Not surprisingly, mutation of the BMP-response element in the hepcidin promoter impairs hepcidin activation in response to IL-6 indicating that an intact BMP/SMAD signalling pathway is required for hepcidin to respond appropriately to inflammation (24) .
Inflammation is a very strong inducer of hepcidin expression. In our studies, we found that the increase in hepcidin expression in following LPS treatment was not affected by quite a strong erythropoietic stimulus, the response to phenylhydrazine-induced haemolysis. The haematological changes induced by this agent were of a similar magnitude to those observed in humans with severe anaemia. Haemolysis alone was able to significantly depress Hamp mRNA levels in our study. These data suggest that despite the negative influence of enhanced erythropoiesis, the BMP/SMAD pathway remained sufficiently active to allow normal LPS-dependent JAK/STAT signalling. In related studies in mice, Santos and colleagues similarly showed that the increase in erythropoiesis accompanying hypoxia was insufficient to block an LPS-induced increase in hepcidin expression, even though hypoxia alone significantly reduced hepcidin levels (36) . In contrast, when erythropoiesis was increased by four consecutive days of treatment with supraphysiological doses of erythropoietin, the hepcidin response to LPS was blunted, although not abolished (36) . The same group also found that the capacity of erythropoietin to reduce the LPS stimulation of hepcidin was dose-dependent, with smaller doses having relatively little effect (36) . Overall these studies suggest that if the erythropoietic stimulus is strong enough and prolonged, the effect of a concomitant inflammatory response can be blunted. This makes sense physiologically. In acute inflammatory situations the primary response is one of high hepcidin and iron withholding by the tissues. This serves to reduce the amount of circulating iron that could act as a virulence factor for invading pathogens or lead to tissue injury by promoting oxidative damage.
However, in chronic inflammatory situations the impaired iron supply can lead to iron-restricted erythropoiesis. Since iron is essential for the production of new red cells, when the erythropoietic demand increases sufficiently the influence of the inflammatory stimulus will be at least partially overridden to ensure some iron supply to the marrow.
A somewhat different outcome was observed when we examined the effects of chronic iron deficiency on the response of hepcidin to inflammation. In this case, systemic iron deficiency ameliorated the acute inflammatory induction of hepcidin in response to LPS. LPS still had a strong effect on hepcidin expression, but the maximum level achieved remained significantly lower in iron deficient rats than in those on an iron replete diet. Constante et al. have also examined this situation and, in contrast to our study, they observed similar levels of hepcidin in LPS treated control and iron deficient animals (37) . There are several possible explanations for this apparent discrepancy, but the most likely is the relative strengths of the different stimuli involved.
The Constante study utilized a very high dose of LPS (5mg/kg) relative to the much lower dose (0.1mg/kg) used in our study. The level of LPS we used is similar to levels achieved in human patients with septicaemia and thus more closely approximates the levels found in vivo (38) . In addition, the rats we studied were more iron deficient than the mice investigated by Constante et al. Thus the relative strength of the signal to reduce hepcidin expression was much greater in our investigations.
The iron dependency of the LPS response appears to manifest itself at two levels. The first is the response of macrophages to LPS. LPS activates the NFκB pathway after binding to its receptor, TLR4, on monocytes and macrophages (39) . The presence of iron is critical for NFκB activation and it has been shown previously that iron supplementation accentuates activation of NFκB and induction of NFκB responsive genes like IL-6 and TNFα (32) (33) (34) .
Consistent with these studies, we found that serum IL-6 and TNFα levels were hypo-responsive to LPS treatment in iron deficient animals, and earlier investigations by others have reported low levels of proinflammatory cytokines in iron deficient individuals (40) . Similarly, macrophages treated with iron chelators demonstrated lower IL-6 transcript levels and lower NFκB activation when challenged with LPS compared to cells treated with LPS alone (33) .
These data indicate that iron deficiency leads to decrease in the general acute inflammatory response in vivo, so it is not surprising that the general inflammatory marker α2m also responded less robustly in iron deficient animals treated with LPS. Overall, these data suggest that the reduced response of hepcidin to LPS in iron deficient animals is in part due to iron (12) . Our data are entirely consistent with the proposal that iron does indeed signal through the BMP/SMAD system, and that an intact BMP/SMAD pathway is required for a response to IL-6, but further studies are required to investigate the mechanism by which DFO exerts its effects in this system.
Since the expression of BMP6 is iron dependent (42) , it is possible that iron deficiency could exert its effects, at least partially, through a reduction in BMP6 levels.
Taken together, the data in this study and those from the literature indicate that the relative strengths of the various stimuli that alter hepcidin expression and the directions of these regulatory events combine to determine the net expression of this important regulatory peptide. Inflammation is a very strong inducer of hepcidin, but even its effects can be counteracted to some degree by iron deficiency and enhanced erythropoiesis. In the experimental setting the stimuli that are applied to alter hepcidin levels are relatively strong (e.g a strong inflammatory stimulus or severe iron deficiency), so in vivo the interplay of milder interactions is likely to be very important. An example of such competing stimuli in vivo comes from the analysis of patients suffering from β-thalassemia (or mice with this condition). Such individuals initially have low hepcidin levels due to high rate of erythropoiesis, but as iron stores accumulate with time, hepcidin levels increase and iron absorption drops in spite of the continued presence of high rate of erythropoiesis (43) . As our understanding of the molecular basis of hepcidin regulation becomes clearer, so will our understanding of what determines the final hepcidin concentration in such complex in vivo situations. Table 1 . Hematocrit and liver iron levels in 9-10 week old female rats treated with a single dose of PHZ (100 mg/kg i.p.) and/or LPS (0.1 mg/kg i.p) 4 days and 6 hours prior to euthanasia respectively. Data are presented as mean ± SEM and group sizes varied from 4-11 animals as indicated. Table 2 . Hematocrit, serum iron and liver iron levels in 9-10 week old male rats on control or iron deficient diets treated with a single dose of LPS (0.1 mg/kg i.p) 6 hours prior to euthanasia. Data are presented as mean ± SEM and group sizes varied from 12-14 animals as indicated. 
